Important note:
Unless otherwise indicated, this policy will apply to all lines of business.
Even though this policy may indicate that a particular service or supply may be considered medically necessary and thus covered, this conclusion is not based upon the terms of your particular benefit plan. Each benefit plan contains its own specific provisions for coverage and exclusions. Not all benefits that are determined to be medically necessary will be covered benefits under the terms of your benefit plan. You need to consult the Evidence of Coverage (EOC) or Summary Plan Description (SPD) to determine if there are any exclusions or other benefit limitations applicable to this service or supply. If there is a discrepancy between this policy and your plan of benefits, the provisions of your benefits plan will govern. However, applicable state mandates will take precedence with respect to fully insured plans and self-funded non-ERISA (e.g., government, school boards, church) plans. Unless otherwise specifically excluded, Federal mandates will apply to all plans. Not all benefits that are determined to be medically necessary will be covered benefits under the terms of your benefit plan. CMS's Coverage Issues Manual can be found on the CMS website. Similarly, for Medicaid-linked plans, the Texas Medicaid Provider Procedures Manual (TMPPM) supersedes coverage guidelines in this policy where applicable.

SERVICE: Urinary and Fecal Incontinence: Biofeedback, Sacral Nerve Stimulation, Posterior Tibial Nerve Stimulation

PRIOR AUTHORIZATION: Required for Sacral Nerve Stimulator

POLICY: Please review the plan’s EOC (Evidence of Coverage) or Summary Plan Description (SPD) for coverage details.

For Medicare plans, please refer to appropriate Medicare NCD (National Coverage Determination) or LCD (Local Coverage Determination).

For Medicaid plans, please confirm coverage as outlined in the Texas Medicaid TMPPM.

Commercial lines of business will use the criteria set forth in InterQual®. When the InterQual® criteria-set only includes Medicare sources, i.e., National or Local Coverage Determinations, those sources will be used to review requests for commercial lines of business.

Similarly, for Medicaid lines of business, if the service is a benefit and criteria are not set forth in the TMPPM, Medicaid lines will use InterQual as indicated for commercial lines above.

Additional guidance:

Urinary Incontinence/Retention:

Biofeedback:

Biofeedback is not a covered benefit under many BSWHP policies, however, if the contract does provide coverage, prior authorization is NOT required. Biofeedback for urinary incontinence is not a treatment; it is a tool to help patients learn how to perform pelvic muscle exercises (Kegel exercises). BSWHP may cover physical therapy which includes instruction in performance of pelvic muscle exercise when medically appropriate. Once proficiency is achieved further biofeedback therapy would not be covered.

Sacral nerve stimulation (SNS): Use InterQual® as directed above

Transurethral RF Therapy (Renessa Procedure)
SWHP considers transurethral radiofrequency therapy (Renessa procedure) for the treatment of stress urinary incontinence experimental, investigational and/or unproven.

**Posterior Percutaneous Tibial Nerve Stimulation: (PTNS)**

*Posterior Tibial Nerve Stimulation* consists of insertion of a percutaneous needle above the medial malleolus into a superficial branch of the posterior tibial nerve. An adjustable low voltage electrical impulse (10mA, 1-10 Hz frequency) travels via the posterior tibial nerve to the sacral nerve plexus to alter pelvic floor function by neuromodulation.

*Posterior Percutaneous Tibial Nerve Stimulation* may be considered medically necessary for the treatment of medically diagnosed **overactive bladder** which has failed standard pharmacotherapy.

- BSWHP considers an initial treatment plan of up to 12 weekly, 30-minute sessions, medically necessary.
- Patients must report an improvement in symptoms within 12 weeks (i.e., 12 sessions) of initiation of PTNS for continued coverage.
- Treatment beyond the initial 12 sessions will be allowed at a frequency of 1 every 1 to 2 months for up to 12 months **IF** there is documentation of 50% decrease in symptoms as evidenced by a daily uro-log (i.e., record of bladder events, voiding diary) and an improvement in quality of life.
- Treatments after 12 months are considered experimental/investigational.

**Bedwetting Alarms:**

These are commercially available without a prescription and therefore are not covered by the health plan.

**Fecal Incontinence**

**Sacral Nerve Stimulator for Fecal Incontinence:** Use InterQual® as directed above.

**Interventions that are NOT considered medically necessary:**

- Solesta - an injectable gel, is considered experimental and investigational.
- Botox - is considered experimental and investigational.

**OVERVIEW:**

**URINARY INCONTINENCE:**

Urinary incontinence, defined as the involuntary loss of urine, is common, particularly in women.

There are four prevalent types of UI in adults: a) stress incontinence (urine loss that occurs with an increase in abdominal pressure, and is often due to urethral hypermobility.), b) urge incontinence (which is thought to be related to detrusor over activity.), c) overflow incontinence (dribbling or leaking associated with incomplete bladder emptying), and d) mixed stress and urge incontinence.

Treatments for UI pelvic muscle exercises (Kegel exercise), behavioral therapies such as bladder training and/or biofeedback, pharmacotherapies (e.g., anticholinergic agents, musculotropic relaxants, calcium channel blockers, tricyclic antidepressants, or a combination of anticholinergic, antispasmodic medications and tricyclic antidepressants), and a variety of surgical procedures.
including intraurethral injection of Coaptite, and implantation of an artificial urinary sphincter. Specifically, urge incontinence is more effectively managed with peripherally acting receptor agonists or antagonists while stress incontinence is better controlled by pelvic muscle exercises, behavioral therapies, or corrective surgery.

FECAL INCONTINENCE:

Fecal incontinence (FI) is loss of control of the bowels resulting in involuntary excretion of liquid or solid feces. The prevalence of FI ranges from 1% to 8% in healthy individuals and approaches 30% in institutionalized patients. FI affects 20 million non-institutionalized adults in the United States. FI has a negative impact on activities of daily living and quality of life. Current treatments for FI range from conservative measures aimed at reducing symptoms to surgical interventions intended to correct anal sphincter or pelvic floor abnormalities.

Sacral nerve stimulation, also called sacral nerve modulation, involves the application of a mild electrical pulse to the sacral nerves through a surgically implanted neuromodulation system to treat fecal incontinence. The electrical pulses modulate the sacral nerves that influence the functioning of the bladder, bowel, urinary, and anal sphincters, and the pelvic floor muscles. The InterStim Therapy System is manufactured by Medtronic.

MANDATES: There are no mandated benefits or regulatory requirements.

CODES:

Important note:

CODES: Due to the wide range of applicable diagnosis codes and potential changes to codes, an inclusive list may not be presented, but the following codes may apply. Inclusion of a code in this section does not guarantee that it will be reimbursed, and patient must meet the criteria set forth in the policy language.

<table>
<thead>
<tr>
<th>CPT Codes:</th>
</tr>
</thead>
<tbody>
<tr>
<td>53444 - Insertion of tandem cuff (dual cuff)</td>
</tr>
<tr>
<td>64561 – Percutaneous implantation of neurostimulator electrode array; sacral nerve (transforaminal placement) including image guidance, if performed,</td>
</tr>
<tr>
<td>53445 - Insertion of inflatable urethral/bladder neck sphincter, including placement of pump, reservoir, and cuff</td>
</tr>
<tr>
<td>64561 - Percutaneous implantation of neurostimulator electrode array; sacral nerve (transforaminal placement) including image guidance,</td>
</tr>
<tr>
<td>64566 – Posterior tibial neurostimulation, percutaneous needle electrode, single treatment, includes programming,</td>
</tr>
<tr>
<td>64581 – Incision for implantation of neurostimulator electrode array; sacral nerve (transforaminal placement),</td>
</tr>
<tr>
<td>64585 - Revision or removal of peripheral neurostimulator electrode array</td>
</tr>
<tr>
<td>64590 –Insertion or replacement of peripheral or gastric neurostimulator pulse generator or receiver, director or inductive coupling,</td>
</tr>
<tr>
<td>64595 – Revision or removal of peripheral or gastric neurostimulator pulse generator or receiver,</td>
</tr>
<tr>
<td>95970 – Electronic analysis of implanted neurostimulator pulse generator system; simple or complex brain, spinal cord, or peripheral neurostimulator pulse generator/transmitter, without reprogramming</td>
</tr>
<tr>
<td>95971 - Electronic analysis of implanted neurostimulator pulse generator system; simple spinal cord, or peripheral neurostimulator pulse generator/transmitter, with intraoperative or subsequent programming,</td>
</tr>
</tbody>
</table>
95972 - Electronic analysis of implanted neurostimulator pulse generator system; complex spinal cord, or peripheral (except cranial nerve) neurostimulator pulse generator/transmitter, with intraoperative or subsequent programming

CPT Codes NOT covered
53860 - Transurethral radiofrequency micro-remodeling of the female bladder neck and proximal urethra for stress urinary incontinence

HCPCS Codes:
A4290 - Sacral nerve stimulation test lead, each
C1767 - Generator, neurostimulator (implantable), nonrechargeable
C1767 - Generator, neurostimulator (implantable), nonrechargeable
C1767 - Generator, neurostimulator (implantable), nonrechargeable
C1767 - Generator, neurostimulator (implantable), nonrechargeable
C1767 - Generator, neurostimulator (implantable), nonrechargeable
C1767 - Generator, neurostimulator (implantable), nonrechargeable
C1767 - Generator, neurostimulator (implantable), nonrechargeable
C1767 - Generator, neurostimulator (implantable), nonrechargeable
C1767 - Generator, neurostimulator (implantable), nonrechargeable
C1767 - Generator, neurostimulator (implantable), nonrechargeable
C1767 - Generator, neurostimulator (implantable), nonrechargeable

ICD10:
N31.0 - N31.9 - Bladder atony
N39.4 – N39.498 – Other specified urinary incontinence
N36.44 Muscular disorders of urethra
N39.4 – N39.498 – Other specified urinary incontinence
N36.44 Muscular disorders of urethra
N39.3 Stress incontinence (female) (male)
N39.41 Urge incontinence
N39.46 Mixed incontinence
R15.x Incontinence of feces
R30.1 Vesical tenesmus
R32 Unspecified urinary incontinence
R33.0 - R33.9 - Urinary retention
R35.0 Frequency of micturition
R39.11 Hesitancy of micturition
R39.14 Feeling of incomplete bladder emptying
R39.2 Extrarenal uremia
R39.81 Functional urinary incontinence
R39.89 Other symptoms and signs involving the genitourinary system
R39.9 Unspecified symptoms and signs involving the genitourinary system


POLICY HISTORY:

<table>
<thead>
<tr>
<th>Status</th>
<th>Date</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>New</td>
<td>12/6/2010</td>
<td>New policy</td>
</tr>
<tr>
<td>Reviewed</td>
<td>11/15/2012</td>
<td>Reviewed.</td>
</tr>
<tr>
<td>Reviewed</td>
<td>11/14/2013</td>
<td>ICD10 codes added.</td>
</tr>
</tbody>
</table>
MEDICAL COVERAGE POLICY
SERVICE: Incontinence Treatment

Policy Number: 052
Effective Date: 06/01/2023
Last Review: 04/27/2023
Next Review Date: 04/27/2024

Reviewed 09/25/2014 Updated LCD information and SNS and PTNS criteria accordingly
Reviewed 10/22/2015 New LCD. Coverage for fecal incontinence added.
Reviewed 12/02/2015 Reviewed with pelvic surgery team and made mild modifications.
Reviewed 10/27/2016 Minor format changes
Reviewed 09/19/2017 Policy language clarification
Reviewed 03/13/2017 Corrected indications to include retention.
Updated 10/01/2018 Added one HCPCS code C1767
Reviewed 06/27/2019 No significant changes
Updated 05/28/2020 Transitioned to IQ and aligned for FirstCare and SWHP
Reviewed 05/27/2021 No major change. Codes updated
Reviewed 04/21/2022 No changes
Reviewed 04/27/2023 No changes

REFERENCES:
The following scientific references were utilized in the formulation of this medical policy. SWHP will continue to review clinical evidence related to this policy and may modify it at a later date based upon the evolution of the published clinical evidence. Should additional scientific studies become available and they are not included in the list, please forward the reference(s) to SWHP so the information can be reviewed by the Medical Coverage Policy Committee (MCPC) and the Quality Improvement Committee (QIC) to determine if a modification of the policy is in order.

14. National Institute for health and Clinical Excellence (NICE). The care and treatment of women aged 18 years and older with urinary incontinence (stress, urgency or mixed urinary incontinence or overactive bladder).


InterStim Continence Control Therapy/Sacral Nerve Stimulation:


Solesta references:


Fecal Incontinence references:


Note: Health Maintenance Organization (HMO) products are offered through Scott and White Health Plan dba Baylor Scott & White Health Plan, and Scott & White Care Plans dba Baylor Scott & White Care Plan. Insured PPO and EPO products are offered through Baylor Scott & White Insurance Company. Scott and White Health Plan dba Baylor Scott & White Health Plan serves as a third-party administrator for self-funded employer-sponsored plans. Baylor Scott & White Care Plan and Baylor Scott & White Insurance Company are wholly owned subsidiaries of Scott and White Health Plan. These companies are referred to collectively in this document as Baylor Scott & White Health Plans.

RightCare STAR Medicaid plans are offered through Scott and White Health Plan in the Central Managed Care Service Area (MRSA) and STAR and CHIP plans are offered through SHA LLC dba FirstCare Health Plans (FirstCare) in the Lubbock and West MRSA.s. Individual HMO plans are offered through FirstCare in West Texas.